January 2, 2018 / 1:11 PM / in 10 minutes BRIEF-Seattle Genetics says FDA grants its Hodgkin Lymphoma treatment priority review status Reuters Staff 1 Min Read 
Jan 2 (Reuters) - Seattle Genetics Inc: 
* FDA ACCEPTS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION AND GRANTS PRIORITY REVIEW FOR ADCETRISÂ® (BRENTUXIMAB VEDOTIN) IN FRONTLINE ADVANCED HODGKIN LYMPHOMA 
* SEATTLE GENETICS INC - FDA GRANTED PRIORITY REVIEW FOR APPLICATION, AND PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE IS MAY 1, 2018 Source text for Eikon: Further company coverage: